A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Clinical trial NCT05716087 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05716087
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-21
- Primary completion
- 2024-12-05
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.